OBJECTIVES: To evaluate the efficiency, in terms of incremental cost-effectiveness ratios (ICER), of human chorionic gonadotropin (hCG) and human gonadotropins, drugs used for male infertility due to hormonal disorder hypogonadotropic hypogonadism (HH), whose female partner has or doesn’t have infertility problems, in the context of an assisted reproduction program. METHODS: Two different decision trees were developed to assess ICER of hCG and human gonadotropins. Firstly, hCG was compared to no treatment; secondly, human gonadotropins in combination with hCG were compared to hCG used alone. Effectiveness was measured as pregnancy and spermatogenesis respectively. Data were obtained from clinical studies, as well as efficacy of medical procedures. The proportion of couples, who needed fertility procedures, was determined according to experts’ opinion. A ministry of health perspective was taken. Costs of medications were based on acquisition costs in 2012 Canadian dollars. Costs of medical procedures, as intrauterine insemination (IUI), in vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI) were based on 2012 fees of Québec’s physicians. The time horizons adopted were based on the durations of drug treatment in clinical studies. RESULTS: The use of hCG in comparison with no treatment is cost-effective with an ICER of 20,915$CAN per man with HH for whom the partner got pregnant. Determinist sensitivity analyses showed that the ratio is more sensitive to the probability to use IVF or ICSI. In the second comparison, treatment with human gonadotropins is cost-effective with an ICER of 25,076$CAN per man that obtained spermatogenesis. Drug dosage is the element for which the ICER is more sensitive in the univariate determinist sensitivity analyses. CONCLUSIONS: Human gonadotropins and hCG are cost-effective for the treatment of men with HH. They can be reimbursed in the drug program for this indication with some restrictions about the duration of treatment.